Shimizu K, Maitani Y, Takayama K, Nagai T
Department of Pharmaceutics, Hoshi University, Tokyo, Japan.
J Drug Target. 1996;4(4):245-53. doi: 10.3109/10611869608995626.
We investigated multilamellar vesicle (MLV) liposomes composed of dipalmitoylphosphatidylcholine (DPPC) and a soybean-derived sterylglucoside mixture (SG) (DPPC/SG-liposomes) for targeting liver parenchymal cells after administration via the tail vein in mice, using liposome-entrapping calcein. The accumulation of DPPC/SG(7:2, mole ratio, DPPC:SG = 7:2)-liposomes in the liver was the highest among DPPC/SG-liposomes. About 80% and 40% of the dose of DPPC/SG(7:2)-liposomes accumulated in the liver at 15 min and 2 h, respectively, but about 20% of DPPC/SG(7:3.5, 7:7)-liposomes accumulated at 2 h after an intravenous administration. However, the uptake of DPPC/SG(7:2, 7:3.5, 7:7)-liposomes by liver parenchymal cells was about 7 times greater than that in non-parenchymal cells irrespective of the SG concentration in liposomes. The uptake of DPPC/SG(7:2)-liposomes in liver was almost the same level as that by liposomes containing lactocylceramide (LC) (LC-liposomes) that were already known to be taken up in liver parenchymal cells by the asialoglycoprotein receptor. DPPC/SG(7:2)-liposomes effectively targeted liver, having optimal stability and SG.
我们使用包裹了钙黄绿素的脂质体,研究了由二棕榈酰磷脂酰胆碱(DPPC)和大豆来源的甾醇糖苷混合物(SG)组成的多层囊泡(MLV)脂质体(DPPC/SG-脂质体)经小鼠尾静脉给药后对肝实质细胞的靶向作用。在DPPC/SG-脂质体中,DPPC/SG(摩尔比为7:2,即DPPC:SG = 7:2)-脂质体在肝脏中的蓄积量最高。静脉注射后,DPPC/SG(7:2)-脂质体剂量的约80%和40%分别在15分钟和2小时时蓄积在肝脏中,但DPPC/SG(7:3.5、7:7)-脂质体在2小时时的蓄积量约为20%。然而,无论脂质体中SG的浓度如何,肝实质细胞对DPPC/SG(7:2、7:3.5、7:7)-脂质体的摄取量比非实质细胞大约高7倍。肝脏中DPPC/SG(7:2)-脂质体的摄取水平与含乳糖神经酰胺(LC)的脂质体(LC-脂质体)几乎相同,已知LC-脂质体可通过去唾液酸糖蛋白受体被肝实质细胞摄取。DPPC/SG(7:2)-脂质体具有最佳的稳定性和SG,能有效靶向肝脏。